CLINICAL TRIALS PROFILE FOR ACETYLCYSTEINE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for ACETYLCYSTEINE
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT01005810 ↗ | A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 2009-09-01 | This study is investigating how N-Acetylcysteine (NAC), an over-the-counter medication, will reduce marijuana use when combined with Contingency Management, a behavioral treatment. It is hypothesized that marijuana dependent adolescents who are treated with NAC will use less marijuana during treatment when compared to adolescents who receive a placebo. |
| OTC | NCT01005810 ↗ | A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana | Completed | Medical University of South Carolina | Phase 2 | 2009-09-01 | This study is investigating how N-Acetylcysteine (NAC), an over-the-counter medication, will reduce marijuana use when combined with Contingency Management, a behavioral treatment. It is hypothesized that marijuana dependent adolescents who are treated with NAC will use less marijuana during treatment when compared to adolescents who receive a placebo. |
| New Formulation | NCT01118663 ↗ | Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection | Terminated | Cumberland Pharmaceuticals | Phase 3 | 2010-09-01 | The primary purpose of this study is determine if a new formulation of Acetadote is at least as effective as the current formulation in the prevention and treatment of acetaminophen overdose related liver injury. |
| OTC | NCT01241513 ↗ | Induced Changes in Ventilatory Responsiveness and Altitude Exposure | Terminated | United States Army Research Institute of Environmental Medicine | Phase 4 | 2010-11-01 | The main purpose of this study is to determine if a drug (acetyl-cysteine or ACCY) can increase the amount of oxygen in your body at a high altitude of 11,500 feet. ACCY is approved by the Food and Drug Administration (FDA) as a treatment or antidote for Tylenol overdoses. Other forms of ACCY are also sold over-the-counter as nutritional supplements. In this study, the FDA-approved form of ACCY will be used "off-label" (meaning in a way not approved by the FDA). This study is being conducted by researchers from the United States Army Research Institute of Environmental Medicine (USARIEM). The study will take place in the Altitude Chamber located in the basement of USARIEM. A total of approximately 30 volunteers (men and women, military and civilians) will take part in the study. They can expect to be in the study for a minimum of a few hours each day for two weeks. The investigators hypothesize that ACCY will improve ventilation and oxygenation while at altitude. |
| OTC | NCT03238300 ↗ | Neuroscience-Informed Treatment Development for Adolescent Alcohol Use | Recruiting | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 2017-10-16 | This study will examine the effect of N-Acetylcysteine (NAC), an over-the-counter antioxidant supplement, on brains of youth (ages 15-19) using magnetic resonance imaging (MRI). 55 adolescents will receive, in a counterbalanced order, a 10-day course of NAC 1200 mg twice daily and a subsequent 10-day course of matched placebo twice daily, separated by 11 days. Urine and blood samples will be collected at baseline and urine samples again before and after each course of medication treatment. Participants will receive a 1- hour MRI scan at baseline and after each treatment trial. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for ACETYLCYSTEINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003346 ↗ | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma | Completed | National Cancer Institute (NCI) | Phase 2 | 1997-11-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy consisting of acetaminophen plus carmustine in treating patients who have stage III or stage IV melanoma. |
| NCT00003346 ↗ | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma | Completed | Memorial Sloan Kettering Cancer Center | Phase 2 | 1997-11-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy consisting of acetaminophen plus carmustine in treating patients who have stage III or stage IV melanoma. |
| NCT00004467 ↗ | Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen | Completed | University of Texas | Phase 3 | 1998-06-01 | OBJECTIVES: I. Determine the safety and efficacy of a short course (72 hours) of intravenous acetylcysteine in patients with acute liver failure for whom no antidote or specific treatment is available. |
| NCT00004467 ↗ | Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen | Completed | University of Texas Southwestern Medical Center | Phase 3 | 1998-06-01 | OBJECTIVES: I. Determine the safety and efficacy of a short course (72 hours) of intravenous acetylcysteine in patients with acute liver failure for whom no antidote or specific treatment is available. |
| NCT00004467 ↗ | Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 3 | 1998-06-01 | OBJECTIVES: I. Determine the safety and efficacy of a short course (72 hours) of intravenous acetylcysteine in patients with acute liver failure for whom no antidote or specific treatment is available. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ACETYLCYSTEINE
Condition Name
Clinical Trial Locations for ACETYLCYSTEINE
Trials by Country
Clinical Trial Progress for ACETYLCYSTEINE
Clinical Trial Phase
Clinical Trial Sponsors for ACETYLCYSTEINE
Sponsor Name
